| This article has been cited by |
| 1 | Healthy volunteers in first-in-human oncology drug development for small molecules | |
| Begoña de las Heras,Dalila Bouyoucef-Cherchalli,Lesley Reeve,Andreas Reichl,Debra Mandarino,Stephen Flach,Laura Vidal,Emilie M. J. van Brummelen,Neeltje Steeghs |
| British Journal of Clinical Pharmacology.2022;88(4)1773 |
| [DOI] |
|
| 2 | Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds | |
| Igor Radanovic,Naomi Klarenbeek,Robert Rissmann,Geert Jan Groeneveld,Emilie M. J. van Brummelen,Matthijs Moerland,Jacobus J. Bosch |
| Frontiers in Oncology.2022;12(4)1773 |
| [DOI] |
|
| 3 | Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds | |
| Shadreck Mwale |
| Frontiers in Oncology.2017;12(4)1 |
| [DOI] |
|
| 4 | Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds | |
| Shadreck Mwale |
| Frontiers in Oncology.2017;12(4)1 |
| [DOI] |
|
| 5 | A Clinical Review of Biosimilars Approved in Oncology | |
| Dat Ngo,Jason Chen |
| Annals of Pharmacotherapy.2021;55(3)362 |
| [DOI] |
|
| 6 | First-in-Human, Healthy Volunteers Integrated Protocol of
ETC
-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug | |
| Vincenzo Teneggi,Veronica Novotny-Diermayr,Lay Hoon Lee,Maryam Yasin,Pauline Yeo,Kantharaj Ethirajulu,Sylvia Bong Hwa Gan,Stephanie E. Blanchard,Ranjani Nellore,Dhananjay N. Umrani,Roberto Gomeni,Darren Lim Wan Teck,Greg Li,Qing Shu Lu,Yang Cao,Alex Matter |
| Clinical and Translational Science.2020;13(1)57 |
| [DOI] |
|
| 7 | A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker | |
| Christine Huynh,Andrea Henrich,Daniel S. Strasser,Marie-Laure Boof,Mohamed Al-Ibrahim,Henriette E. Meyer Zu Schwabedissen,Jasper Dingemanse,Mike Ufer |
| Clinical Pharmacology & Therapeutics.2021;109(6)1648 |
| [DOI] |
|
| 8 | Reviewing the role of healthy volunteer studies in drug development | |
| Joyson J. Karakunnel,Nam Bui,Latha Palaniappan,Keith T. Schmidt,Kenneth W. Mahaffey,Briggs Morrison,William D. Figg,Shivaani Kummar |
| Journal of Translational Medicine.2018;16(1)1648 |
| [DOI] |
|
| 9 | Unveiling changes in the landscape of patient populations in cancer early drug development | |
| Cinta Hierro,Analía Azaro,Guillem Argilés,Elena Elez,Patricia Gómez,Joan Carles,Jordi Rodon |
| Oncotarget.2017;8(8)14158 |
| [DOI] |
|
| 10 | Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development | |
| Mariam A. Ahmed,Chirag Patel,Nicole Drezner,Whitney Helms,Weiwei Tan,Daria Stypinski |
| Clinical and Translational Science.2020;13(1)31 |
| [DOI] |
|
| 11 | Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis | |
| Yvonne Schuller,Christine Gispen-de Wied,Carla E. M. Hollak,Hubertus G. M. Leufkens,Violeta Stoyanova-Beninska |
| The Journal of Clinical Pharmacology.2019;59(2)229 |
| [DOI] |
|
